Rozanolixizumab

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Trial Timeline

— → —

NCT ID

NCT05014724

About Rozanolixizumab

Rozanolixizumab is a pre-clinical stage product being developed by UCB for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The current trial status is completed. This product is registered under clinical trial identifier NCT05014724. Target conditions include Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

What happened to similar drugs?

20 of 20 similar drugs in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) were approved

Approved (20) Terminated (3) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05014724	Pre-clinical	Completed	—	—	Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07465289	Phase 3	Recruiting	Jul 27, 2026	Jan 23, 2031	Ocular Myasthenia Gravis
NCT07246564	Approved	Recruiting	Dec 1, 2025	Oct 15, 2027	Myasthenia Gravis
NCT06720714	Phase 1	Completed	Dec 3, 2024	May 12, 2025	Healthy Participants
NCT06540144	Phase 3	Recruiting	Oct 8, 2024	Aug 17, 2027	Generalized Myasthenia Gravis
NCT06149559	Phase 2/3	Recruiting	Jun 14, 2024	Aug 17, 2026	Generalized Myasthenia Gravis
NCT05681715	Phase 3	Completed	Apr 17, 2023	Apr 23, 2024	Generalized Myasthenia Gravis
NCT05643794	Phase 2	Completed	Dec 21, 2022	Jul 9, 2024	Fibromyalgia
NCT05063162	Phase 3	Active	Feb 2, 2022	Jul 1, 2027	Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
NCT04828343	Phase 1	Completed	Apr 22, 2021	Apr 11, 2022	Healthy Study Participants
NCT04650854	Phase 3	Completed	Feb 3, 2021	Jan 25, 2024	Generalized Myasthenia Gravis
NCT04596995	Phase 3	Terminated	Jan 6, 2021	Dec 21, 2022	Primary Immune Thrombocytopenia
NCT04224688	Phase 3	Terminated	Jun 3, 2020	May 5, 2022	Primary Immune Thrombocytopenia
NCT04200456	Phase 3	Terminated	Jan 31, 2020	Apr 27, 2022	Primary Immune Thrombocytopenia
NCT04124965	Phase 3	Completed	Oct 29, 2019	Sep 1, 2021	Generalized Myasthenia Gravis
NCT04051944	Phase 2	Completed	Aug 21, 2019	Nov 10, 2021	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT03971422	Phase 3	Completed	Jun 3, 2019	Oct 26, 2021	Generalized Myasthenia Gravis
NCT03861481	Phase 2	Completed	Mar 26, 2019	Mar 31, 2021	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Competing Products

20 competing products in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

See all competitors

Product	Company	Stage	Hype Score
Levofloxacin 500	Dr. Reddy's Laboratories	Pre-clinical	23
mRNA-0184	Moderna	Phase 1	0
Lubiprostone + Lubiprostone + Placebo	Dr. Reddy's Laboratories	Phase 3	37
macitentan 10 mg	BML, Inc.	Phase 3	32
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
LY3556050 + Placebo	Eli Lilly	Phase 2	35
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
LY3526318 + Placebo	Eli Lilly	Phase 2	35
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
LYR-210	Lyra Therapeutics	Phase 2	25